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A B S T R A C T   
The 3T3-L1 murine pre-adipocyte line is an established cell culture model for screening Metabolism Disrupting 
Chemicals (MDCs). Despite a need to accurately identify MDCs for further evaluation, relatively little research 
has been performed to comprehensively evaluate reproducibility across laboratories, assess factors that might 
contribute to varying degrees of differentiation between laboratories (media additives, plastics, cell source, etc.), 
or to standardize protocols. As such, the goals of this study were to assess interlaboratory variability of efficacy 
and potency outcomes for triglyceride accumulation and pre-adipocyte proliferation using the mouse 3T3-L1 pre- 
adipocyte cell assay to test chemicals. Ten laboratories from five different countries participated. Each laboratory 
evaluated one reference chemical (rosiglitazone) and three blinded test chemicals (tributyltin chloride, pyr-
aclostrobin, and bisphenol A) using: 1) their Laboratory-specific 3T3-L1 Cells (LC) and their Laboratory-specific 
differentiation Protocol (LP), 2) Shared 3T3-L1 Cells (SC) with LP, 3) LC with a Shared differentiation Protocol 
(SP), and 4) SC with SP. Blinded test chemical responses were analyzed by the coordinating laboratory. The 
magnitude and range of bioactivities reported varied considerably across laboratories and test conditions, though 
the presence or absence of activity for each tested chemical was more consistent. Triglyceride accumulation 
activity determinations for rosiglitazone ranged from 90 to 100% across test conditions, but 30–70 % for pre- 
adipocyte proliferation; this was 40–80 % for triglyceride accumulation induced by pyraclostrobin, 80–100 % 
for tributyltin, and 80–100 % for bisphenol A. Consistency was much lower for pre-adipocyte proliferation, with 
30–70 % active determinations for pyraclostrobin, 30–50 % for tributyltin, and 20–40 % for bisphenol A. Greater 
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consistency was observed for the SC/SP assessment. As such, working to develop a standardized adipogenic 
differentiation protocol represents the best strategy for improving consistency of adipogenic responses using the 
3T3-L1 model to reproducibly identify MDCs and increase confidence in reported outcomes.   
1. Introduction 
The 3T3-L1 murine pre-adipocyte cell line is an established model for 
in vitro screening of metabolism disrupting chemicals (MDCs) (Heindel 
et al., 2015, 2017). When exposed to adipogenic stimuli, pre-adipocytes 
will differentiate into mature adipocytes, undergo morphological 
changes, accumulate triglycerides, and eventually develop into a 
rounded white fat cell with a number of large lipid droplets often dis-
placing the nucleus (Green and Meuth, 1974; Green and Kehinde, 1975). 
Adipocyte differentiation requires eventual activation of the peroxisome 
proliferator-activated receptor-gamma (PPARγ), often considered the 
“master regulator” of adipocyte differentiation (Rosen et al., 1999). 
Molecular pathways upstream that contribute to this activation are 
diverse and include modulation of thyroid receptor-beta (TRβ), gluco-
corticoid receptor (GR), estrogen receptor (ER), androgen receptor (AR), 
liver X receptor (LXR), retinoid X receptor (RXR), and others (Niemelä 
et al., 2008), including non-receptor mediated mechanisms (Bournat 
and Brown, 2010; Kassotis and Stapleton, 2019; Luz et al., 2018). These 
receptor pathways are highly conserved across vertebrate species (Fu 
et al., 2005; Zhao et al., 2015), suggesting that mechanisms of adipo-
genesis are highly translatable. Indeed, active MDCs identified using 
3T3-L1 cells and other in vitro models (increased triglyceride accumu-
lation/differentiation, pre-adipocyte proliferation, etc.) have been 
routinely shown to be active in vivo, such as bisphenol A and tributyltin 
chloride, among others (Angle et al., 2013; Chamorro-Garcia et al., 
2013; Li et al., 2011; Masuno et al., 2005). Compounds that modulate 
these receptors belong to diverse chemical classes (Fang et al., 2015; 
Hamers et al., 2006; Orton et al., 2011), and many are frequently 
detected in indoor environments and in human tissues (Hoffman et al., 
2015; Kitamura et al., 2005; Meerts et al., 2000; Shen et al., 2009; 
Stapleton et al., 2009, 2011; Takeuchi et al., 2005). A number of these 
chemicals have been associated with adiposity, obesity, type 2 diabetes, 
and other chronic metabolic health conditions in humans (Gore et al., 
2015; Heindel et al., 2015, 2017; Ruiz et al., 2018). As such, there is a 
critical need to ensure robust and validated models that promote highly 
reproducible toxicological outcomes across laboratories. 
Despite a need to accurately identify MDCs, relatively little research 
has been performed to comprehensively evaluate reproducibility across 
laboratories, and comprehensively assess factors that might contribute 
to varying degrees of differentiation among laboratories. Previous 
research has described diverse differentiation success and declining 
performance over time with various cell bank stocks of 3T3-L1 cells 
(Zebisch et al., 2012). Cell culture vessel size and proprietary tissue 
culture coatings have also been demonstrated to influence differentia-
tion success of 3T3-L1 cells (Mehra et al., 2007), and various cell line 
suppliers provide disparate protocols and techniques for eliciting 
maximal differentiation success (American Type Culture Collection 
(ATCC) ATTC, 2011; Zenbio Inc, 2015). Other providers suggest an 
inability to differentiate their 3T3-L1 cell stocks, with timelines of 2–5 
weeks and very limited differentiation (European Collection of 
Authenticated Cell Cultures (ECACC), 2020). Despite these notable gaps, 
reproducibility studies across toxicological studies are limited, and often 
conducted only within the establishment of guideline assays such as 
Organisation for Economic Co-operation and Development (OECD) test 
guidelines. Chemists, in contrast, have demonstrated robust success in 
improving methodology and laboratory-specific measurement reli-
ability through participation in interlaboratory reproducibility pro-
grams (Boyer et al., 1985; Ikonomou et al., 2012; M.Weiss et al., 2013; 
Voet et al., 1999; Wong et al., 2010). For example, recent initiatives to 
improve measurements for novel brominated and organophosphate 
flame retardants have demonstrated high precision between technical 
replicates within laboratories but not as strong accuracy for measuring 
the provided values across laboratories (Melymuk et al., 2015, 2018). 
Importantly, analytical reproducibility studies benefit from the concrete 
nature of the outcome: chemicals can be included at specific, known 
concentrations, making the determination of the “correct” result more 
straightforward than possible in toxicological studies. A limited number 
of studies have attempted this with endocrine outcomes such as mea-
surement of nuclear receptor activation (Hettwer et al., 2018; Mehinto 
et al., 2015; Zava et al., 1982), reporting variable consistency across 
trials and pathways, with variances often seemingly resulting from 
non-harmonized protocols. 
We previously published an assessment of some disparities in adi-
pogenic cell culture systems under various conditions (Kassotis et al., 
2017b). Specifically, both cell line (3T3-L1 vs. OP9) and source (ATCC 
vs. Zenbio 3T3-L1) had a significant impact on the responses to various 
chemicals. Ligands for LXR, RXR, GR, and TR promoted disparate re-
sponses between cell sources (Kassotis et al., 2017b), in some cases 
apparently mediated through gene expression differences. We also noted 
significant differences based on the cell culture plastic utilized, with 
different 96-well plates contributing to <50 % reduction in maximal fold 
induction differences and appreciably altering chemical potencies 
(Kassotis et al., 2017b). Cytotoxicity and proliferative response differ-
ences were also observed among plates, in some cases negatively 
impacting the ability to even detect chemicals acting via pre-adipocyte 
proliferation (Kassotis et al., 2017b). Significant differences were also 
noted in both triglyceride accumulation and DNA content among 
different differentiation induction times (7, 10, 14 days) (Kassotis et al., 
2017b), and it is still unclear what differences might stem from the wide 
degree of heterogeneity in media additives across varying differentia-
tion protocols. For example, while many researchers do not include 
dexamethasone in the differentiation cocktail (Boucher et al., 2015; 
Kassotis et al., 2017a, 2018; Kassotis et al., 2019; Sargis et al., 2010), 
others use a 1000-fold range of concentrations (Li et al., 2011; Masuno 
et al., 2002; Temkin et al., 2016; Zebisch et al., 2012). Differing pro-
tocols and cell culture supplies utilized may contribute to a lack of 
reproducibility and bias in measuring adipogenic potency and efficacy 
of chemicals between laboratories. Importantly, while reported previ-
ously, these factors have never been assessed in a systematic manner 
across laboratories. 
As such, the objectives of this study were to evaluate the inter-
laboratory variability in the response of 3T3-L1 cells to the exposures of 
several chemical compounds. Given previous reports of inconsistencies 
in responses using this model, we sought to comprehensively evaluate 
the underlying factors and how they might influence differences in ef-
ficacy (magnitude of effects) and/or potency (concentration of effects) 
for both triglyceride accumulation (marker of differentiation success) 
and pre-adipocyte proliferation (marker of cell number). To accomplish 
this, we assessed three blinded test chemicals (bisphenol A, BPA; trib-
utyltin chloride, TBT; pyraclostrobin) between ten laboratories in the 
United States, Canada, Italy, Norway, and the United Kingdom. These 
data should provide comprehensive insight into the most important 
factors that influence the assay’s responses and to inform strategies to 
increase interlaboratory reproducibility. 
2. Materials and methods 
2.1. Chemicals 
Chemicals for use in bioassays were purchased as follows: 
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rosiglitazone (Sigma cat # R2408, ≥ 98 %), pyraclostrobin (Sigma cat # 
33696, 99.9 %), tributyltin chloride (TBT; Aldrich cat # T50202, 96 %), 
and bisphenol A (BPA; Sigma cat # 239658, >99 %). Stock solutions 
were prepared in 100 % cell-culture grade DMSO (Sigma cat # D2650) 
and stored at − 20 ◦C between uses. Laboratories were recruited via a 
scientific conference discussion and coordination via a metabolism 
disruption research listserv. Rosiglitazone (1 mM) was provided as a 
labeled amber glass vial, and laboratories were instructed to dilute the 
solution 1000-fold and then perform four 10-fold dilutions (0.1 nM – 1 
μM in contact with cells). Pyraclostrobin, TBT, and BPA (10 mM) were 
provided as blinded chemicals (Chemicals A, B, and C, respectively) in 
amber glass vials, and laboratories were instructed to perform the same 
1000-fold dilution and four 10-fold dilution scheme (1 nM – 10 μM). 
2.2. Sample shipments 
Packages were shipped to participating laboratories in insulated 
Styrofoam shipping boxes with between one and five kilograms of dry 
ice, depending on distance of shipment. All packages were shipped 
priority overnight, generally resulting in next day domestic delivery; 
however, international shipments often took as long as ten days to clear 
customs and be delivered by local couriers. Additional dry ice was added 
by Fedex as necessary to ensure packages arrived frozen, and this was 
confirmed by receiving laboratories upon receipt. Given the long length 
of delivery for certain participating international laboratories, a cryo-
shipper was utilized (Chart MVE BL-7) to allow for improved assurance 
on the frozen cell stock. 
2.3. Testing, differentiation, and evaluation protocol 
The following materials were provided to each laboratory (Fig. 1). 
One vial of murine 3T3-L1 cells (Zenbio cat# SP-L1-F, lot# 3T3062104; 
Research Triangle Park, NC), one vial NucBlue® Live ReadyProbes® 
Reagent (Thermo cat # R37605), one vial of laboratory prepared Nile 
Red reagent (40 μg/mL Nile Red in acetone; Sigma 72485− 100MG), one 
sleeve containing six black clear-bottom 96-well tissue culture plates 
(Greiner cat # 655090; four for assays and two replacements), one vial 
of DMSO for use as a solvent control, one vial of rosiglitazone for use as a 
positive control, and three vials containing the blinded test chemicals. A 
shared differentiation protocol, differentiation data sheet, and test in-
structions were emailed to each participating laboratory. Differentiation 
data sheets included spaces to include raw fluorescence values from Nile 
Red and NucBlue outputs, a plate map to denote placement of all test 
chemicals and replicates, and spaces to specify differentiation details, 
media constituents, and other assay details. The shared differentiation 
protocol was adapted based on a previously published protocol (Zebisch 
et al., 2012) and has been described in detail previously (Kassotis et al., 
2017a, b). A short protocol was provided to detail the desired test 
conditions. Laboratories were requested to prepare media according to 
the shared differentiation protocol and according to their own protocols 
and then test blinded test chemicals under four sets of conditions: 1) 
using their laboratory-specific differentiation protocol, media, and 
supplies along with laboratory-specific stock of 3T3-L1 cells (LC/LP), 2) 
using their laboratory-specific differentiation protocol, media, and 
supplies along with the provided stock of 3T3-L1 cells (SC/LP), 3) using 
the provided differential protocol, media prepared according to the 
shared protocol, and using the included cell culture plates along with 
laboratory-specific stock of 3T3-L1 cells (LC/SP, and 4) using the pro-
vided differential protocol, media prepared according to the shared 
protocol, and using the included cell culture plates along with the pro-
vided stock of 3T3-L1 cells (SC/SP, Fig. 1). 
Fig. 1. Study Design and Test Conditions. 
Schematic of the study design and test condi-
tions. Ten laboratories were recruited from the 
United States and other countries. The 
following materials were provided to each lab-
oratory: one vial of 3T3-L1 cells, one vial 
NucBlue® Live ReadyProbes® Reagent, one vial 
of laboratory prepared Nile Red reagent, black 
clear-bottom 96-well tissue culture plates, 
DMSO, rosiglitazone, and three vials containing 
the blinded test chemicals. A shared differenti-
ation protocol, differentiation data sheet, and 
test instructions were emailed to each partici-
pating laboratory. A short protocol was pro-
vided to detail the desired test conditions. 
Laboratories were requested to prepare media 
according to the shared differentiation protocol 
and according to their own protocols and then 
test blinded test chemicals under four sets of 
conditions: 1) using their laboratory-specific 
differentiation protocol, media, and supplies 
along with laboratory-specific stock of 3T3-L1 
cells, 2) using their laboratory-specific differ-
entiation protocol, media, and supplies along 
with the provided stock of 3T3-L1 cells, 3) using 
the provided differential protocol, media pre-
pared according to the shared protocol, and 
using the included cell culture plates along with 
laboratory-specific stock of 3T3-L1 cells, and 4) 
using the provided differential protocol, media 
prepared according to the shared protocol, and 
using the included cell culture plates along with 
the provided stock of 3T3-L1 cells (For inter-
pretation of the references to colour in this 
figure legend, the reader is referred to the web 
version of this article).   
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2.4. 3T3-L1 cell care and differentiation assays 
Zenbio 3T3-L1 cells were provided to all laboratories and were used 
for SC test conditions. Laboratory-specific cell sources of 3T3-L1 cells 
(LC) varied depending on the laboratory and are detailed within Table 1. 
The shared protocol called for cells to be maintained in pre-adipocyte 
media (Dulbecco’s Modified Eagle Medium – High Glucose; DMEM- 
HG; Gibco cat# 11995, supplemented with 10 % bovine calf serum 
and 1% penicillin and streptomycin; Gibco cat# 15140). These cells 
were seeded in pre-adipocyte media into 96-well tissue culture plates 
(Greiner cat # 655090) at approximately 30,000 cells/well and grown to 
confluency; after confluency, cells were allowed 48 h to undergo growth 
arrest and initiate clonal expansion. Media was then replaced with 
controls, and/or blinded test chemicals using a DMSO vehicle (at 0.1 %) 
in differentiation media (DMEM-HG with 10 % fetal bovine serum, 1% 
penicillin/streptomycin, 1.0 μg/mL human insulin, and 0.5 mM 3-isobu-
tyl-1-methylxanthine, IBMX). After 48 h of differentiation induction, 
media was replaced with fresh dilutions of test chemicals in adipocyte 
maintenance media (differentiation media without IBMX), and this 
media was refreshed every 2–3 days until assay, ten days after induction. 
Laboratory-specific protocols varied among laboratories, with variations 
to this general protocol specified within Table 1. 3T3-L1 cells were 
utilized between passages 8 (at shipment) and 12 (provided Zenbio 
cells) or as noted in Table 1 for laboratory-specific cells, and were 
maintained in a sub-confluent state until differentiation. 
2.5. 3T3-L1 triglyceride accumulation, cell proliferation, and cell viability 
measurements 
Fluorescence endpoint measurements were measured using a plate 
reader for the shared protocol tests and using standard laboratory 
practice for laboratory-specific protocol tests. For shared protocol ex-
periments, media was removed from plates, and cells were rinsed with 
Dulbecco’s phosphate-buffered saline (DPBS; Gibco cat # 14040) before 
replacing with 200 μL of a live-cell dye mixture (19 mL DPBS, 1 drop/mL 
NucBlue® Live ReadyProbes® Reagent (cell proliferation/cytotoxicity 
measure of DNA content; Thermo cat # R37605) and 500 μL Nile Red 
(intracellular lipid measure of triglyceride accumulation; 40 μg/mL in 
acetone; Sigma 72485− 100MG) per plate). Plates were protected from 
light and incubated at room temperature for approximately forty mi-
nutes; fluorescence was then measured on plate readers with excitation 
485 nm/emission 572 nm (previously demonstrated to be ideal wave-
lengths for intracellular neutral lipids (Greenspan et al., 1985)) and/or 
485/535 (more accessible, generally used) for Nile Red and 360/460 for 
NucBlue®. Measurement wavelengths varied for laboratory-specific 
protocols, with most laboratories also providing their data from plate 
readers using these wavelengths. 
All laboratories provided raw data, and as such, normalizations and 
activity calculations and determinations were made in a uniform 
manner for all data. For triglyceride accumulation data, percent activ-
ities were calculated relative to the maximal rosiglitazone-induced fold 
induction over intra-assay differentiated vehicle control (0.1 % dime-
thylsulfoxide, DMSO) responses, after correcting for background fluo-
rescence. Rosiglitazone was utilized as the positive control herein 
(provided as an unblinded chemical stock to all laboratories) due to 
selective, robust, and potent activation of PPARγ (Lehmann et al., 1995; 
Seimandi et al., 2005; Spiegelman, 1998) and in order to provide ease of 
comparisons across laboratories and experiments. DNA content was 
calculated as percent change from differentiated vehicle control (0.1 % 
DMSO) responses for each chemical at each concentration and was then 
used to normalize total triglyceride values to obtain triglyceride content 
per unit DNA (proxy for triglyceride accumulation per cell). Four tech-
nical (replicates within each assay plate) and two biological replicates 
(separate cell passages/assays) were requested for every test chemical 
and concentration herein. 
2.6. Statistical analysis 
Data for adipogenic activities (triglyceride accumulation and pre- 
adipocyte proliferation) are presented as means ± standard error of 
the mean (SEM) from replicates. First, the median of four technical 
replicates (within plates) was determined and then medians of two or 
three (depending on laboratory) biological replicates (separate experi-
mental plates) were averaged to provide a final value for each chemical 
for each laboratory under each test condition. Efficacy values were 
defined as the percent maximal activity relative to the rosiglitazone- 
induced maximal response for each laboratory and test condition. 
Relative potency values (effective concentration, EC20; concentration of 
each chemical that exhibits 20 % of assay maximal activity, respec-
tively) values were estimated from raw fluorescence data, setting the 
axis to 20 % of response and estimating the concentration at which the 
response curve passes this activation value. Values were extrapolated as 
necessary for efficacy and potency values for samples approaching the 
cut-off; potency values were not extrapolated when there was no 
apparent activity (samples not approaching 20 % activity), as potencies 
cannot be calculated for inactive chemicals/samples. Sensitivity was 
defined as the lowest concentration that exhibited a significant effect for 
each chemical above its own solvent control under each set of test 
conditions for each laboratory. To ease comparisons among laboratories, 
a uniform limit of quantification was set between laboratories as follows: 
a biological activation threshold approach was utilized, where the 
variation in the differentiated solvent (0.1 % DMSO) control was 
calculated as the average differentiated solvent value plus three times 
the standard deviation of the differentiated solvent control response. All 
reproducibility metrics were based on the raw, unadjusted data to assess 
variance within experimental groups and across laboratories; they were 
calculated by subtracting the average experimental group response from 
each individual laboratory response and dividing by the standard de-
viation. Values further from zero in either direction represent greater 
variation from the average experimental group response. Responses 
were analyzed using a one-way ANOVA and Dunnett’s post-hoc test. 
Differences between treatment and control groups were considered 
statistically significant at p < 0.05. 
3. Results 
Ten participating laboratories were asked to test three blinded test 
chemicals and one standard positive control chemical (rosiglitazone) 
under a defined concentration range and four defined sets of conditions 
(Fig. 1). Laboratories were asked to test using a shared differentiation 
protocol to assess the potential differences contributed by differentia-
tion protocol variations and using a shared source of 3T3-L1 cells to 
assess potential differences contributed by variations in cell sources. 
Activity determinations were assessed as presence of significant activity 
above the biological activation threshold as described in the methods, 
and were based on triglyceride accumulation (standard marker for 
extent of differentiation) and pre-adipocyte proliferation (increase in 
DNA content relative to differentiated solvent controls). 
3.1. Rosiglitazone responses across laboratories and test conditions 
Rosiglitazone was tested under four sets of conditions within each 
laboratory (Fig. 2). Given that triglyceride accumulation efficacies for 
rosiglitazone were normalized to the maximal intra-assay rosiglitazone- 
induced response, maximal efficacies (percent activation) could not be 
compared and fold induction responses relative to the differentiated 
solvent control were used instead. Maximal triglyceride accumulation 
fold inductions for rosiglitazone did not vary considerably across the 
four test conditions (2.5–3.2-fold), with the highest fold induction re-
sponses observed in the shared protocol groups (Table S1, Fig. 2). More 
variation was observed among laboratories relative to among test con-
ditions, with fold inductions ranging from 1.3–6.0 (agnostic of test 




Descriptive Statistics for Laboratory-Specific Differentiation Protocols.   














TC Plate TC plate # Base 
Media 
IBMX Insulin Dexamethasone Biotin Ca 
Pantothenate 
FBS 






250 nM – – Wisent #090150, 
Lot#115680 
Lab 2 ATCC 700009858 u + 3, 9 10 10 2 Greiner 
BioOne 






250 nM – – Euroclone, ECS0180 
L, lot # 
EUS0040912 






250 nM – – Sigma F6178, Lot 
#013K8411 
Lab 4 ATCC MBX clone1 u + 5 10 10 2 Greiner 
BioOne 








17 mM Fisher Scientific 
(Gibco) 10437− 028 
Lab 5 ATCC 2268173 u + 9 14 14 2 Greiner 
BioOne 






20 nM – – Sigma #F2442, lot 
1982183 
Lab 6 ATCC – u + 3, 8 10 10 2 Greiner 
BioOne 






1 mM – – GE Healthcare life 
sciences, 
SH30910.03HI 








– – – GIBCO; Ref: 
10270− 106; Lot: 
41G1780K 






1.25 mM 2 mg/ 
L 
1 mg/L Gemini #100− 106 
Lab 9 Zenbio 3T3L1062104 10 10 10 2 Greiner 
CellStar 






– – – Sigma F9665 
Lab 10 ATCC – u + 4 11 11 2 USA 
Scientific 






1 mM – – Hyclone 
SH30541.03 
Shared Zenbio 3T3L1062104 8 10 10 2 Greiner 
BioOne 






– – –  
Descriptive statistics for laboratory-specific differentiation protocols provided by each participating laboratory. These cells and differentiation details were utilized for the LC and LP conditions only. The “Shared” cell 
source was utilized for all SC conditions, and the shared protocol (Supplemental information) for all SP conditions. All laboratories completed tests using each of the four defined test conditions. 
u = unknown passage number. 
Differentiation length specifies the total duration of adipocyte differentiation and adipocyte maintenance media treatment, whereas cocktail length specifies just the duration of the differentiation induction media 
treatment. 
1 3T3-L1 MBX clone utilized for these experiments: designed to ensure more complete adipocyte differentiation and insulin sensitivity; unknown lot #. 
2 Green H (isolating laboratory) source as gift from Philip Pekala (same apparent source as commercial Zenbio cells); no reported lot #. 
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conditions; Table S2) and Z-scores exceeding ± 1.0. Lower variances 
were again observed in the shared protocol groups. With some excep-
tions, most laboratories reported the highest fold induction responses 
using the shared cell/shared protocol (SC/SP) test conditions. Dose re-
sponses were varied when laboratories utilized laboratory-specific cells 
and laboratory-specific protocols (LC/LP), with more than two orders of 
magnitude difference in potencies, three orders of magnitude difference 
in lowest observed effect level (LOEL; lowest tested concentration with 
significant increase above baseline), two orders of magnitude in 
maximal effective concentration, and a wide range of fold inductions 
relative to differentiated solvent controls (0.1 % DMSO; Fig. 2, 
Table S2). Similar variances were observed when all laboratories used 
the SC, with no apparent improvement in responses across laboratories, 
though variances improved slightly in the SP conditions (e.g. maximal 
concentrations demonstrated much greater consistency). Mean 
potencies (EC20) for triglyceride accumulation were very similar, with 
values ranging from 0.009 μM for SC/SP, 0.004 for LC/SP, 0.006 for SC/ 
LP, and 0.008 for LC/LP, though these trends were not evidence for pre- 
adipocyte proliferation (mean potencies of 18.45 μM for SC/SP, 146.72 
for LC/SP, 0.17 for SC/LP, and 6.00 for LC/LP). For most laboratories, 
fold induction increased when using the shared protocol (with or 
without shared cells). Mean SC/SP metrics for rosiglitazone perfor-
mance (triglyceride accumulation) were 0.04 ± 0.01 μM for LOEL, 0.72 
± 0.14 μM for maximal response concentration, 3.2 ± 0.4 for fold in-
duction of response, and 0.02 ± 0.01 μM for potency (Table S2). 
Pre-adipocyte proliferation means/deviations did not appreciably 
change across the test groups, though a greater proportion of labora-
tories reported significant adipogenic activity when using SC (with the 
most consistency using SC/SP; Fig. 1, Table S1, Table S2). Only one 
laboratory reported inactivity for pre-adipocyte proliferation using the 
Fig. 2. Rosiglitazone Responses Across Laboratories and Conditions. Comparison of dose responses for rosiglitazone (provided, not blinded) across the ten 
participating laboratories. Responses are provided as raw triglyceride accumulation per well of tissue culture plate, normalized to maximal rosiglitazone-induced 
response using those test conditions (left column); cell proliferation and/or cytotoxicity as per Hoechst DNA dye (middle column); and normalized triglyceride 
accumulation per cell, normalized to DNA content of that treatment (right column). Laboratories were asked to test equivalent concentrations using their laboratory 
stock of 3T3-L1 cells and their laboratory differentiation protocol (top row), using the provided stock of 3T3-L1 cells and their laboratory protocol (second row), 
using their laboratory stock of 3T3-L1 cells and the provided protocol (third row), and using the provided 3T3-L1 cells and provided protocol (bottom row). 
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SC/SP, while 30–60 % of laboratories reported inactivity when assessed 
under the other test conditions. Efficacy ranged from < limit of detection 
(LOD) to ~80 % increased DNA content relative to the differentiated 
solvent control, and the magnitude of proliferation seemed to be highest 
in the SC/SP group (Table S1, Table S2). Average reproducibility metrics 
for the SC/SP conditions included LOEL (mean: 0.26 ± 0.13 μM), 
maximal efficacy (mean: 32.1 % ± 6.7 %), concentration at which 
maximal response was induced (mean: 0.9 ± 0.1 μM), and potency 
(18.45 ± 15.63 μM; Table S2). Maximal response concentration was 
nearly unanimous using the SC/SP, but large variances and potency 
shifts were observed in the other test groups (Fig. 1, Table S2). Some 
low-level cytotoxicity was observed for certain laboratories under 
certain test conditions, only at 10 mM, and all using the LC test 
conditions. 
3.2. Pyraclostrobin responses across laboratories and conditions 
Pyraclostrobin is a fungicide that has been reported previously to 
exhibit adipogenic effects (Kassotis et al., 2017a; Luz et al., 2018), 
though reportedly not through PPARγ activation (Luz et al., 2018). 
Maximal triglyceride accumulation efficacies for pyraclostrobin varied 
considerably across test conditions (<LOD – 400 %), with generally 
lower variances observed in the SP groups (Table S3, Table S4, 
Figure S1). Under each set of test conditions, there was at least one 
laboratory below or near the LOD for triglyceride accumulation. There 
appeared to be two groupings among laboratories for maximal efficacy 
Fig. 3. Pyraclostrobin Responses Across Labs and Conditions. Comparison of dose responses for pyraclostrobin across the ten participating laboratories. Mean 
responses ± standard error of the mean (SEM) are provided as raw triglyceride accumulation per well of tissue culture plate, normalized to maximal rosiglitazone- 
induced response using those test conditions (left column); cell proliferation and/or cytotoxicity as per Hoechst DNA dye (middle column); and normalized tri-
glyceride accumulation per cell, normalized to DNA content of that treatment (right column). Laboratories were asked to test equivalent concentrations using their 
lab stock of 3T3-L1 cells and their laboratory differentiation protocol (top row), using the provided stock of 3T3-L1 cells and their laboratory protocol (second row), 
using their lab stock of 3T3-L1 cells and the provided protocol (third row), and using the provided 3T3-L1 cells and provided protocol (bottom row). Dashed lines 
represent concentrations at which cytotoxicity was observed (significant decreased DNA content at that concentration). 
C.D. Kassotis et al.                                                                                                                                                                                                                             
Toxicology 461 (2021) 152900
8
results (low/no activity responders and high activity responders; Fig. 3). 
Three laboratories were consistently low responders, one was consis-
tently a high responder, four laboratories were high responders in three 
of the four test conditions (test condition varied by laboratory), and two 
laboratories were split in responses across test conditions. The LOEL and 
maximal response concentrations appeared to be more consistent when 
using the SP, albeit with slightly lower potencies (particularly for the 
SC/SP condition; Fig. 3, Table S4). Almost all laboratories identified this 
chemical as active for inducing triglyceride accumulation with the 
exception of one each using LC/SP and SC/SP (blue boxes denote active 
determinations, whereas red denote inactive; Fig. 3, Table S3, Table S4). 
For pre-adipocyte proliferation, maximal efficacies also varied 
widely (<LOD – 201 %; Fig. S1, Fig. 3, Table S4). A greater proportion of 
laboratories reported significant proliferative activity using the SC: 30 % 
using LC/LP, 40 % using LC/SP, 70 % using SC/LP, and 60 % using SC/ 
SP. In most cases, greater efficacies for proliferation were observed 
when in SP groups. Greater consistency but lower sensitivity/potency 
were observed for the SC/SP group. At the level of activity determina-
tion, there was an almost even split in responses (Fig. 3D). Only five 
laboratories reported pyraclostrobin as active for proliferation in three 
or more four conditions (generally reported as inactive using LC/LP). 
Significant toxicity was observed for some laboratories under certain 
test conditions. No toxicity was observed for any laboratory in the SC/SP 
condition, but 40 % of laboratories reported significant toxicity in both 
the SC/LP (one at 1 and 10 mM and three at 10 mM only) and LC/SP 
(three at 1 and 10 mM and one at 10 mM only) conditions, and 50 % 
Fig. 4. Tributyltin Chloride Responses Across Labs and Conditions. Comparison of dose responses for tributyltin chloride across the ten participating labora-
tories. Mean responses ± standard error of the mean (SEM) are provided as raw triglyceride accumulation per well of tissue culture plate, normalized to maximal 
rosiglitazone-induced response using those test conditions (left column); cell proliferation and/or cytotoxicity as per Hoechst DNA dye (middle column); and 
normalized triglyceride accumulation per cell, normalized to DNA content of that treatment (right column). Laboratories were asked to test equivalent concentrations 
using their lab stock of 3T3-L1 cells and their laboratory differentiation protocol (top row), using the provided stock of 3T3-L1 cells and their laboratory protocol 
(second row), using their lab stock of 3T3-L1 cells and the provided protocol (third row), and using the provided 3T3-L1 cells and provided protocol (bottom row). 
Dashed lines represent concentrations at which cytotoxicity was observed (significant decreased DNA content at that concentration). 
C.D. Kassotis et al.                                                                                                                                                                                                                             
Toxicology 461 (2021) 152900
9
reported significant toxicity using LC/LP (two at 0.1, 1, and 10 mM; two 
at 1 and 10 mM; and one at 10 mM only). 
3.3. Tributyltin chloride (TBT) responses across laboratories and 
conditions 
TBT is a biocide that has been reported previously to exhibit robust 
adipogenic effects in vitro (Grun et al., 2006; Li et al., 2011; Pereir-
a-Fernandes et al., 2013) and in vivo (Chamorro-Garcia et al., 2013; 
Penza et al., 2011). Maximal triglyceride accumulation efficacies for 
TBT varied considerably across test conditions (<LOD – 429 %), with 
lower variances in the LC/LP and SC/SP groups (Fig. 4, Fig. S2, Table S5, 
Table S6). Relative to pyraclostrobin, wide variances were observed 
even within laboratories, and two response groupings (high and low 
consistency) were observed. Five laboratories ranged widely in triglyc-
eride accumulation responses across test conditions, and five labora-
tories were more consistent (moderate to high triglyceride 
accumulation). No differences were observed in LOELs, though 
maximum response concentrations and potencies appeared more 
consistent in the SC/SP group, albeit with slightly lower potencies 
(Fig. 4, Table S6). Almost all laboratories identified this chemical as 
active for inducing triglyceride accumulation, with the exception of two 
laboratories using the LC and one using the SC/SP (Fig. 4D). 
For pre-adipocyte proliferation, maximal efficacies had low consis-
tency (<LOD – 84 %; Fig. S2, Fig. 4, Table S6), but the highest consis-
tencies for efficacy, LOEL, and potencies were observed in the SC/SP 
group. At the level of activity determination, 50–70 % of laboratories 
reported TBT as inactive for proliferation across all test conditions 
Fig. 5. Bisphenol A Responses Across Labs and Conditions. Comparison of dose responses for bisphenol A across the ten participating laboratories. Mean re-
sponses ± standard error of the mean (SEM) are provided as raw triglyceride accumulation per well of tissue culture plate, normalized to maximal rosiglitazone- 
induced response using those test conditions (left column); cell proliferation and/or cytotoxicity as per Hoechst DNA dye (middle column); and normalized tri-
glyceride accumulation per cell, normalized to DNA content of that treatment (right column). Laboratories were asked to test equivalent concentrations using their 
lab stock of 3T3-L1 cells and their laboratory differentiation protocol (top row), using the provided stock of 3T3-L1 cells and their laboratory protocol (second row), 
using their lab stock of 3T3-L1 cells and the provided protocol (third row), and using the provided 3T3-L1 cells and provided protocol (bottom row). 
C.D. Kassotis et al.                                                                                                                                                                                                                             
Toxicology 461 (2021) 152900
10
(Fig. 4D), with no laboratory reporting consistent activity across test 
conditions. Two laboratories identified TBT as inactive for proliferation 
for all conditions and two as inactive in three of four conditions. Clear 
cytotoxicity was observed for TBT at 1 and 10 mM, with high consis-
tency across laboratories and conditions (Fig. S2). 
3.4. Bisphenol A responses across laboratories and conditions 
BPA is a synthetic chemical used often as a cross-linker in the syn-
thesis of some plastics and can be found in some consumer products. 
(vom Saal et al., 2007; Welshons et al., 2006) BPA has been extensively 
described to disrupt metabolic health in vitro (Masuno et al., 2002; Sargis 
et al., 2010; Taxvig et al., 2012), in vivo (Angle et al., 2013; Somm et al., 
2009; Vom Saal et al., 2012), and in epidemiological studies (Carwile 
and Michels, 2011; Rochester, 2013; Trasande et al., 2012). Maximal 
triglyceride accumulation efficacies for BPA varied across test condi-
tions (<LOD – 93 %), with apparent lower variances in the SP groups 
(Table S7, Table S8, Fig. S3, Fig. 5). Relatively wide variances were 
observed even within laboratories, and three response groupings 
(inactive, low/moderate and moderate/high activity) were observed. 
Given lower reported activity, potency and LOEL comparisons were 
difficult to ascertain (Fig. 5, Table S8). Nearly all laboratories identified 
this chemical as active for triglyceride accumulation, though with 
considerable variation across test conditions and no apparent difference 
between groups (Fig. 5). 
For pre-adipocyte proliferation, maximal efficacies were again less 
consistent but with a smaller dynamic range (<LOD – 42 %; Fig. S3, 
Fig. 5, Table S8) that hindered evaluation of several reproducibility 
metrics. Greater agreement was observed for inactivity of BPA on the 
proliferation metric (Fig. 5D). Three laboratories reported BPA as 
inactive for proliferation across test conditions, three laboratories as 
inactive in three of four test conditions, and the remaining laboratories 
reported higher rates of activity. Within test conditions, the greatest 
consistency was observed using the SC/LP and SC/SP conditions, with 
80 % of laboratories reporting BPA as inactive for proliferation. No 
significant toxicity was reported for BPA at any test concentration by 
any laboratory and in any test condition. 
4. Discussion 
These results confirm that repeatability of adipogenic (pre-adipocyte 
proliferation) and lipogenic (triglyceride accumulation) responses uti-
lizing 3T3-L1 cells are highly variable across laboratories, which can be 
problematic for reproducibility and data comparability. There have 
been previous reports of inconsistencies in adipogenic determinations 
for specific chemicals (Kassotis et al., 2017b), but this has not previously 
been evaluated in a blinded, systematic manner. While standard in most 
areas, reproducibility studies are relatively uncommon for toxicological 
outcomes, and as a consequence, reproducibility across laboratories is 
not well-appreciated. While bioactivities (efficacies/potencies) varied 
considerably across laboratories and test conditions, activity de-
terminations (active/inactive) were more consistent, which suggests 
that most laboratories can accurately identify MDCs. Though impor-
tantly, even these determinations were less consistent when using 
LC/LP, suggesting that standardization may greatly improve reproduc-
ibility between laboratories (at least for triglyceride accumulation) and 
thus confidence in reported outcomes. The most consistent results across 
test conditions and chemicals tested were generally observed in the 
LC/SP and SC/SP groups. While potencies were lower for 
rosiglitazone-induced triglyceride accumulation in the SC/SP group, this 
pattern did not carry over to other test chemicals or the pre-adipocyte 
proliferation metric, and this group had the most potent responses for 
other test chemicals. 
Pyraclostrobin was selected for screening given the previously re-
ported non-traditional mechanism(s) of action (antagonism of TRb and/ 
or mitochondrial dysfunction) and robust adipogenic response (Kassotis 
et al., 2017a; Luz et al., 2018). A high degree of consistency was 
observed for triglyceride accumulation activity determination between 
laboratories and test conditions for this chemical, though magnitude and 
potency of responses were much more variable. Efficacy did not seem to 
vary based on test conditions, but instead was more laboratory-specific, 
with laboratories reporting more consistent responses regardless of test 
condition. These responses appeared independent of cell source and 
protocol, which could suggest more overarching variables such as fetal 
bovine serum source/consistency that may impact results across these 
conditions. Maximal response concentrations and LOELs were more 
consistent when using the SP, albeit with slightly lower potencies. 
Pre-adipocyte proliferation was much more variable (50 % of labora-
tories and test conditions reported active), though twice the laboratories 
reported significant proliferative activity using the SP. In most cases, 
greater proliferative responses were observed when using the SP, for 
which laboratories were provided tissue culture plates; it has been 
previously reported that the tissue culture plates used could drastically 
impact the proliferative response (Kassotis et al., 2017b; Mehra et al., 
2007). Overall, greater consistency but lower sensitivity/potency were 
observed for the SC/SP group. It is worth noting that pyraclostrobin 
exhibited much greater activity 
TBT was selected due to well-reported adipogenic effects via acti-
vation of PPAR and RXR (Chamorro-Garcia et al., 2013; Grun et al., 
2006; le Maire et al., 2009; Li et al., 2011; Penza et al., 2011; Pereir-
a-Fernandes et al., 2013). We previously demonstrated consistent 
expression for PPAR isoforms and RXRα in ATCC and Zenbio-sourced 
3T3-L1 cells (Kassotis et al., 2017b), suggesting this chemical might 
have greater consistency across laboratories and test conditions. How-
ever, while nearly all laboratories and test conditions successfully 
identified TBT as active for promoting significant triglyceride accumu-
lation, the broad range of efficacies, potencies, and sensitivities reported 
here would suggest that these methods may not be sensitive enough to 
accurately characterize less active chemicals. This could be due to small 
differences in cytotoxicity impacting our broad concentration response 
curves. Pre-adipocyte proliferation is a less frequently examined and/or 
reported endpoint in 3T3-L1 cells, with explicit reporting only becoming 
more standard in the last several years. Accounting for varying cell 
densities across wells and replicates can be achieved by normalizing the 
triglyceride content with the DNA content. Indeed, when examining the 
total triglyceride content per well only (Table S5), the number of labo-
ratories and conditions reporting TBT inactive would increase from five 
to nine. Thus, the normalization to DNA content is important to accu-
rately defining adipogenic activity, particularly given that varying cell 
densities across plates are common and since mature adipocytes detach 
easily from the plate bottom during media changes and rinses. 
Pre-adipocyte proliferation as its own metric, however, was consider-
ably less consistent. Approximately half of the laboratories and test 
conditions reported TBT as inactive for proliferation (17/40) and half as 
active, demonstrating no clear correct determination for this endpoint. 
Greater consistency was observed when using SC/SP, however, 
demonstrating that greater concordance in testing may be possible if 
protocols were standardized. 
BPA was selected due to the non-canonical mechanism of action and 
the less reproducible outcomes reported previously in vitro (Kassotis 
et al., 2017b). BPA has been reported to increase adipogenic gene 
expression (aP2) through an estrogen receptor-mediated mechanism 
(Boucher et al., 2014), which we reported to have differential expression 
between 3T3-L1 cell sources (Kassotis et al., 2017b). As expected, lower 
consistency was observed for BPA-induced triglyceride accumulation 
(65 % of laboratories/conditions reported as active). Lower variance 
was observed for DNA content measurements, with only 30 % of labs 
and test conditions reporting BPA as active for this metric. While test 
condition did not appreciably influence activity determinations for tri-
glyceride accumulation, improved consistency was observed for the 
pre-adipocyte proliferation metric using the LC/SP and SC/SP condi-
tions, suggesting that protocol and not cell differences were the primary 
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factors in these disparities. 
Overall, cell source appeared to be a significant factor in variation 
observed between laboratories and test conditions. Zenbio-sourced cells 
often had lower variation than ATCC-sourced cells for chemicals, which 
we reported previously (Kassotis et al., 2017b). It is perhaps unsur-
prising that 3T3-L1 cells sourced from different companies had high 
variation in responses between them, though it is notable that consid-
erable variation was observed even when comparing cells obtained from 
the same provider (Table 1, Figs. 2–5); cells sourced from the Green Lab 
were unsurprisingly more similar to the Zenbio-sourced cells. It has been 
previously established that ATCC maintains a variety of 3T3-L1 cell lots, 
which are described in ATCC protocols to differentiate to different ex-
tents (Kassotis et al., 2017b). This appears to be a common problem, as 
noted above, as the European Collection of Authenticated Cell Culture 
(ECACC) currently reports that their 3T3-L1 cells will not differentiate. 
It is likely, based on the varied responses reported herein and the dif-
ferentiation issues noted by the providers, that continuity of this cell line 
has not been properly controlled across sources. This may be contrib-
uting to a portion of the divergent responses observed across labora-
tories. As observed here, this contributes to considerable variance even 
for laboratories ordering presumably the same cell line from the same 
supplier. This has been reported previously for MCF-7 cells obtained by 
two laboratories that ordered the same lot of MCF-7 cells from ATCC 
(Kleensang et al., 2016). Phenotypic, gene expression, metabolomic, and 
hormone-responsiveness were all demonstrated to clearly vary between 
these sub-clones even of the same lot of cells and were eventually linked 
to genetic variability in a single frozen lot of ATCC MCF-7 cells 
(Kleensang et al., 2016). As these authors recommended, future research 
should investigate these 3T3-L1 cell sources and lots through Direct 
Compararative Genome Hybridization and/or deep sequencing ap-
proaches to determine shifts in frozen cell line stocks that may be 
contributing to disparate responses. This should be pursued to improve 
response consistency and to increase confidence and transparency of 
results. 
For a number of chemicals and laboratories, the most reproducible 
and least variable outcomes (lower Z-score ranges; Supplemental Ta-
bles) based on the performance metrics examined here were observed in 
the SC/SP group. Often, we observed reduced variance in the LC/SP 
group as well, suggesting that while cell source should be considered as a 
contributory factor in improving reproducibility, improvements can be 
made more readily through taking steps to harmonize differentiation 
protocols across laboratories. Numerous factors varied widely across 
laboratories (Table 1). While the differentiation timeline was often 
consistent, a variety of cell culture plastics were used, concentrations 
and presence of media additives varied considerably. The source of 
additives such as fetal bovine serum have been reported to vary sub-
stantially and may have contributed to varying degrees of differentia-
tion. While isobutylmethylxanthine (IBMX) concentrations were quite 
consistent, insulin concentrations varied >1000-fold, and seven labo-
ratories used dexamethasone (10-fold variation in concentrations). Even 
10-fold variations in insulin concentration have been described to pro-
mote robust impacts on adipogenesis via both triglyceride accumulation 
and pre-adipocyte proliferation (Green and Kehinde, 1975). Addition-
ally, dexamethasone has been demonstrated to promote potent and 
efficacious effects on triglyceride accumulation (Kassotis et al., 2017b). 
Taken together, the concentrations of these additives are likely 
contributory factors, though no clear trends in media additive use could 
be associated with specific patterns of activity (Fig. S4). While the SP 
groups utilized consistent detection and staining protocols, these were 
not consistent in the LP groups and may have contributed to some of the 
protocol-specific variances. Despite these factors, particularly variation 
likely contributed by fetal bovine serum sourcing, we need to utilize 
models such as this to evaluate the tens of thousands of chemicals 
requiring toxicological characterization. Appreciating these factors, and 
understanding the inherent variability, is key to making proper de-
terminations based on studies utilizing these and similar models. 
In summary, we report poor reproducibility (efficacies, potencies, 
and sensitivities) for several blinded test chemicals across laboratories, 
though this largely did not impact determination of chemical activity 
classification (e.g. categorized as “active” or “inactive”). While activity 
determinations for triglyceride accumulation were quite consistent, 
even this gross level of bioactivity measurement was not consistent for 
pre-adipocyte proliferation. These results suggest that toxicologic 
reproducibility assessments are warranted for other endpoints (for other 
assays and other metrics of differentiation success such as percent of 
differentiated cells, etc.) and suggests some avenues for improvements 
through harmonization of cell sourcing and differentiation protocols. It 
is also important to note that analytical reproducibility efforts have also 
reported high variance across laboratories (Melymuk et al., 2015, 2018); 
we do not believe this should reduce confidence in bioassay findings, but 
should be acknowledged to support accurate determinations of activity 
for unknown test chemicals when considering regulatory next steps. We 
report that the differentiation protocol and the source of the 3T3-L1 cells 
both contributed to variance in responses and even some dissimilar 
determinations of activity, suggesting that these factors may provide 
opportunity for reducing inter-laboratory variability. While we did not 
detect specific differences that we could associate with individual media 
additives, further research should evaluate this more explicitly. It should 
be noted that pyraclostrobin exhibited much greater activities than BPA, 
though has received as of yet very limited relative research attention. 
While human mesenchymal stem cell and human pre-adipocyte cell 
lines are increasingly available commercially, there are wide reported 
variations based on sex, race and ethnicity, as well as physiological 
status of the donor. These models should see increased use, and direct 
comparisons to 3T3-L1 results, in future research; however, the decades 
of research on 3T3-L1 cells support continued use of this model at least 
until there are clearly superior models and/or clear translation of prior 
findings to human models. 
Given the increasing need for accurate and reliable metabolic health 
assays and the difficulty of policing cell line providers, we suggest that 
future efforts focus on establishing best practices and consistency in 
differentiation protocols to improve translation across laboratories. 
There are also notable efforts ongoing through the Horizon 2020 pro-
gram in the European Union to develop and validate new and diverse 
metabolism disrupting chemical assays in silico, in vitro, and in vivo 
(Audouze et al., 2020; Legler et al., 2020). Towards that end, we have 
provided the detailed shared differentiation protocol used in this study 
(Supplemental File 1), though further efforts towards harmonization 
should be undertaken with experts to weigh inclusion or exclusion of 
specific factors in the protocol and to consider the issues inherent with 
specific sources of 3T3-L1 cells. 
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Niemelä, S., Miettinen, S., Sarkanen, J.R., Ashammakhi, N., 2008. Adipose tissue and 
adipocyte differentiation: molecular and cellular aspects and tissue engineering 
applications. In: Topics in tissue engineering, Vol. 4, 1–26. 
Orton, F., Rosivatz, E., Scholze, M., Kortenkamp, A., 2011. Widely used pesticides with 
previously unknown endocrine activity revealed as in vitro anti-androgens. Environ. 
Health Perspect. 119, 794–800. 
Penza, M., Jeremic, M., Marrazzo, E., Maggi, A., Ciana, P., Rando, G., et al., 2011. The 
environmental chemical tributyltin chloride (TBT) shows both estrogenic and 
adipogenic activities in mice which might depend on the exposure dose. Toxicol. 
Appl. Pharmacol. 255, 65–75. 
Pereira-Fernandes, A., Vanparys, C., Hectors, T.L., Vergauwen, L., Knapen, D., Jorens, P. 
G., et al., 2013. Unraveling the mode of action of an obesogen: mechanistic analysis 
of the model obesogen tributyltin in the 3T3-L1 cell line. Mol. Cell. Endocrinol. 370, 
52–64. 
Rochester, J.R., 2013. Bisphenol a and human health: a review of the literature. Reprod. 
Toxicol. 42, 132–155. C.  
Rosen, E.D., Sarraf, P., Troy, A.E., Bradwin, G., Moore, K., Milstone, D.S., et al., 1999. 
PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. 
Mol. Cell 4, 611–617. 
Ruiz, D., Becerra, M., Jagai, J.S., Ard, K., Sargis, R.M., 2018. Disparities in environmental 
exposures to endocrine-disrupting chemicals and diabetes risk in vulnerable 
populations. Diabetes Care 41, 193–205. 
Sargis, R.M., Johnson, D.N., Choudhury, R.A., Brady, M.J., 2010. Environmental 
endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through 
glucocorticoid receptor activation. Obesity Silver Spring (Silver Spring) 18, 
1283–1288. 
Seimandi, M., Lemaire, G., Pillon, A., Perrin, A., Carlavan, I., Voegel, J.J., et al., 2005. 
Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines 
to selective PPAR synthetic ligands. Anal. Biochem. 344, 8–15. 
Shen, O., Du, G., Sun, H., Wu, W., Jiang, Y., Song, L., et al., 2009. Comparison of in vitro 
hormone activities of selected phthalates using reporter gene assays. Toxicol. Lett. 
191, 9–14. 
C.D. Kassotis et al.                                                                                                                                                                                                                             
Toxicology 461 (2021) 152900
13
Somm, E., Schwitzgebel, V.M., Toulotte, A., Cederroth, C.R., Combescure, C., Nef, S., 
et al., 2009. Perinatal exposure to bisphenol A alters early adipogenesis in the rat. 
Environ. Health Perspect. 117, 1549–1555. 
Spiegelman, B.M., 1998. Ppar-gamma: adipogenic regulator and thiazolidinedione 
receptor. Diabetes 47, 507–514. 
Stapleton, H.M., Klosterhaus, S., Eagle, S., Fuh, J., Meeker, J.D., Blum, A., et al., 2009. 
Detection of organophosphate flame retardants in furniture foam and U.S. House 
dust. Environ. Sci. Technol. 43, 7490–7495. 
Stapleton, H.M., Klosterhaus, S., Keller, A., Ferguson, P.L., van Bergen, S., Cooper, E., 
et al., 2011. Identification of flame retardants in polyurethane foam collected from 
baby products. Environ. Sci. Technol. 45, 5323–5331. 
Takeuchi, S., Iida, M., Kobayashi, S., Jin, K., Matsuda, T., Kojima, H., 2005. Differential 
effects of phthalate esters on transcriptional activities via human estrogen receptors 
alpha and beta, and androgen receptor. Toxicology 210, 223–233. 
Taxvig, C., Dreisig, K., Boberg, J., Nellemann, C., Schelde, A.B., Pedersen, D., et al., 2012. 
Differential effects of environmental chemicals and food contaminants on 
adipogenesis, biomarker release and PPARgamma activation. Mol. Cell. Endocrinol. 
361, 106–115. 
Temkin, A.M., Bowers, R.R., Magaletta, M.E., Holshouser, S., Maggi, A., Ciana, P., et al., 
2016. Effects of crude oil/dispersant mixture and dispersant components on 
PPARgamma activity and : identification of dioctyl sodium sulfosuccinate (DOSS; 
CAS #577-11-7) as a probable obesogen. Environ. Health Perspect. 124, 112–119. 
Trasande, L., Attina, T.M., Blustein, J., 2012. Association between urinary bisphenol A 
concentration and obesity prevalence in children and adolescents. JAMA 308, 9. 
Voet, Hd, JAHv, Rhijn, HJvd, Wiel, 1999. Inter-laboratory, time, and fitness-for-purpose 
aspects of effective validation. Anal. Chim. Acta 391, 159–171. 
vom Saal, F.S., Akingbemi, B.T., Belcher, S.M., Birnbaum, L.S., Crain, D.A., Eriksen, M., 
et al., 2007. Chapel Hill bisphenol A expert panel consensus statement: integration of 
mechanisms, effects in animals and potential to impact human health at current 
levels of exposure. Reprod. Toxicol. 24, 131–138. 
Vom Saal, F.S., Nagel, S.C., Coe, B.L., Angle, B.M., Taylor, J.A., 2012. The estrogenic 
endocrine disrupting chemical bisphenol A (BPA) and obesity. Mol. Cell. Endocrinol. 
354, 74–84. 
Welshons, W.V., Nagel, S.C., vom Saal, F.S., 2006. Large effects from small exposures. III. 
Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. 
Endocrinology 147, S56–69. 
Wong, J., Hao, C., Zhang, K., Yang, P., Banerjee, K., Hayward, D., et al., 2010. 
Development and interlaboratory validation of a QuEChERS-based liquid 
chromatography-tandem mass spectrometry method for multiresidue pesticide 
analysis. J. Agric. Food Chem. 58, 5897–5903. 
Zava, D.T., Wyler-von Ballmoos, A., Goldhirsch, A., Roos, W., Takahashi, A., 
Eppenberger, U., et al., 1982. A quality control study to assess the inter-laboratory 
variability of routine estrogen and progesterone receptor assays. Eur. J. Cancer Clin. 
Oncol. 18, 713–721. 
Zebisch, K., Voigt, V., Wabitsch, M., Brandsch, M., 2012. Protocol for effective 
differentiation of 3T3-L1 cells to adipocytes. Anal. Biochem. 425, 88–90. 
Zenbio Inc, 2015. 3T3-L1 Cell Care Manual - Maintenance and Differentiation of 
Preadipocytes to Adipocytes. Available: http://www.zen-bio.com/pdf/ 
ZBM0009.013T3L1CareprotocolRV08.08.pdf [accessed 30 September 2015. 
Zhao, Y., Zhang, K., Giesy, J.P., Hu, J., 2015. Families of nuclear receptors in vertebrate 
models: characteristic and comparative toxicological perspective. Sci. Rep. 5, 8554. 
C.D. Kassotis et al.                                                                                                                                                                                                                             
